Salute e Benessere
Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
, will present a poster titled " ", showing that simple blood tests measuring liver function at just 90 days after treatment can predict which patients will experience long-term benefits, with those showing early improvements in clotting factors (INR) and liver disease scores (MELD) having the best outcomes. Key findings:
- Among patients treated with Regenerative Macrophages there was a significant reduction in all-cause mortality and a significant increase in transplant-free survival at three years, compared to those who received standard of care, long term clinical outcomes data showed (results presented at AASLD 2024)
- Improvement in liver function at 90 days post-dose, measured using common biomarkers such as INR and MELD, was associated with favourable long term clinical outcomes
- These data demonstrate in humans what was previously observed in preclinical studies
- The data suggest that the initial anti-inflammatory effects of RMT improve liver function and result in later liver remodelling – giving rise to significant long term clinical benefit
,
, will present a poster titled , detailing novel preclinical data of RTX001, Resolution's first engineered RMT, in high-fat diet preclinical models of liver fibrosis. Key findings:
- Single administration of RTX001 in mouse surrogate significantly reduced systemic inflammation in CDAA-HFD models
- This effect was not observed when mice were treated with non-engineered macrophages
- Mouse macrophages engineered with IL-10 and MMP9 demonstrated significantly greater anti-inflammatory effect, compared to non-engineered macrophages
- Distinct molecular signatures of fibrosis progression and regression were identified in the livers of CDAA-HFD mice, providing a new framework to assess anti-fibrotic therapies for end-stage liver disease at a molecular level
,
Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution's initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh , is based in Edinburgh and London . Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. It fosters research that leads to improved treatment options for millions of liver disease patients. It advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
View original content:https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-announces-new-data-showcasing-the-potential-of-regenerative-macrophage-therapy-in-treating-cirrhosis-at-aasld-2025-302607670.html